Results 251 to 260 of about 3,717,417 (345)

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Synchronous Colon Adenocarcinoma and Renal Cell Carcinoma: Diagnostic Challenges and Simultaneous Laparoscopic Management in Two Cases. [PDF]

Diagnostics (Basel)
Iorga C, Iorga CR, Strambu V.
europepmc   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity. [PDF]

J Immunother Cancer
Wang L, Guo Y, Dai Y, Sun W, Huang X, Lei H, Zhang A, Chen S, Li Y, Pan J, Hong Y, Ma L, Feng Y, Shao F, Zeng J, Luo P, Li J, Chen W, Zhou N, Li Y, Sun H, Xu X, Deng CX, Miao K.   +23 more
europepmc   +1 more source

A novel and high-performance tumor inhibitor of La, N co-doped carbon dots for U251 and LN229 cells

Xinyun Ye, Huanglian Zhong, Lin Liu, J. H. Huang, Zhengcai Xia, Zhiji Tang, Wenjin Wei, Weilong Huang, Yuwei Ye, Qiuhua Jiang   +9 more
openalex   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Hepatic resections for metastatic tumors [PDF]

, 1989
Iwatsuki, S, Starzl, TE
core  

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source